drugset / Trial / NCT02376452

Phase II Study of 2-weekly RAILIRI Versus FOLFIRI as Second-line Treatment in Advanced Colorectal Cancer Patients

NCT02376452

Phase 2 Unknown 100 enrolled Fudan University
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is designed to compare the efficacy and safety of two-weekly RAILIRI regimen with FOLFIRI regimen in the treatment of advanced colorectal cancer patients in the second-line setting.

Timeline

Start
2014-09
Primary completion
2015-12
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Raltitrexed Small molecule 2 mg/m2 Intravenous
Comparator fluorouracil Small molecule 400 mg/m2 Intravenous
Comparator fluorouracil Small molecule 2400 mg/m2 Intravenous
Background Irinotecan Small molecule 180 mg/m2 Intravenous
Comparator Leucovorin Small molecule 400 mg/m2 Intravenous

Indications